Company news
Resverlogix Corp. (TSX:RVX) news
Resverlogix Corp. news releases on 6ix. Latest, Jul 12, 2017: Daily Coverage on Healthcare Stocks: BELLUS Health, Helius Medical Technologies, Resverlogix…
Press releases — page 2
Daily Coverage on Healthcare Stocks: BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics
July 12, 2017
Resverlogix Randomizes First Patient in Taiwan/China Portion of the Phase 3 BETonMACE Clinical Trial
July 10, 2017
Resverlogix Announces Fourth Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone
June 28, 2017
Resverlogix Comments on TSX Trader Notes
June 21, 2017
Resverlogix Closes $10 Million of Equity Subscriptions
June 20, 2017
Resverlogix to Raise Up To $10 Million
June 9, 2017
Resverlogix Announces Overnight Marketed Equity Offering
June 8, 2017
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017
June 5, 2017
Research Reports Initiated on Healthcare Stocks BELLUS Health, Helius Medical Technologies, Resverlogix, and Crescita Therapeutics
June 2, 2017
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain
May 31, 2017
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone
May 30, 2017
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success
May 23, 2017
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial
May 15, 2017
Research Reports Initiated on Healthcare Stocks BELLUS Health, Resverlogix, Helius Medical Technologies, and IntelliPharmaCeutics International
March 29, 2017
Resverlogix Announces Third Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone and Provides an Update on Corporate Activities
March 17, 2017
Resverlogix Announces Receipt of Notice of Allowance from the United States Patent and Trademark Office
March 15, 2017
Research Reports Initiated on Healthcare Stocks Resverlogix, Immunovaccine, IntelliPharmaCeutics International, and Aeterna Zentaris
February 24, 2017
Resverlogix Reports Positive FDA Type B Meeting on Design Issues Relating to a Proposed Phase 2a Kidney Dialysis Trial
February 23, 2017
Resverlogix Highlights Unique Properties of Apabetalone in Both a Rare Muscular Dystrophy (FSHD) and Neurodegenerative Eye Disease
February 13, 2017
Resverlogix Provides Groundbreaking Results in Patients with Severe Kidney Impairments
January 23, 2017
Resverlogix Announces Presentation at 9th Annual Biotech Showcase Conference in San Francisco, CA
January 5, 2017
Resverlogix Announces Voting Results From The 2016 Annual And Special Meeting Of Shareholders
December 14, 2016
Resverlogix Announces Second Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
December 5, 2016
Resverlogix Announces Successful Phase 1 Renal Trial Results: Clears Path for Future Phase 2 Studies
November 17, 2016
Resverlogix Announces Annual and Special Meeting of Shareholders
October 6, 2016
Resverlogix To Host Research & Development Update Featuring Key Opinion Leaders in Cardiovascular and Renal Disease
October 4, 2016
Resverlogix Announces Participation in Upcoming Conferences
September 12, 2016
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
August 29, 2016
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board For Phase 3 Study of Apabetalone (RVX-208)
August 11, 2016
Resverlogix Files 2016 Year-End Disclosure Documents
July 27, 2016
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs
July 21, 2016
Resverlogix Announces Corporate Update Webcast
June 9, 2016
Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2016
June 2, 2016
Resverlogix Presents New Complement Data and Establishes Renal Clinical Advisory Board at the 53rd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
May 24, 2016
The New York Academy of Sciences Collaborates with Resverlogix to Host Epigenetics Symposium
April 18, 2016
Resverlogix Further Strengthens the Board of Directors and Appoints a New Chairman
April 4, 2016
Resverlogix's Manuscript on BET-inhibitor apabetalone (RVX-208) Accepted into the Atherosclerosis Journal
January 25, 2016
Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
November 11, 2015
Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference
November 9, 2015
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
October 26, 2015
Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
October 22, 2015
Resverlogix Announces Voting Results
September 30, 2015
Resverlogix Provides Research and Development Update in New York City
September 29, 2015
Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases
September 24, 2015
Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
September 10, 2015
Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor
August 31, 2015
International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"
August 4, 2015
Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
July 21, 2015
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
July 8, 2015
Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement
June 30, 2015